Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Parotitis future or investigational therapies
Introduction
Overview
Overview
Aprotinin, a kallikrein inhibitor, is currently being investigated for treatment of chronic parotitis symptoms. Initial studies have demonstrated its potential to relieve pain, restore normal parotid gland function, and resolve parotid gland swelling. Further research is warranted.
Future or Investigational Therapies
Future or Investigational Therapies
- Aprotinin, a kallikrein inhibitor, is currently being investigated for treatment of chronic parotitis symptoms.[1]
- Kallikrein release in the parotid gland is associated with the inflammatory edema process.
- Aprotinin was administered to 7 recurrent parotitis patients, with the following results observed:
- Pain relieved 12 hours after administration
- Parotid gland function returned to normal 48 hours after administration
- Parotid gland swelling resolved after 7 days.
- More research is warranted on the efficacy of kallikrein inhibition.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Luke Rusowicz-Orazem, B.S.